About Akkermansia
Akkermansia muciniphila is a next-generation probiotic bacterium that resides in the intestinal mucus layer (1–4% of healthy gut microbiota). The pasteurized (heat-killed) form outperformed live bacteria in the only well-designed RCT — unusual for probiotics. Pasteurization increases accessibility of Amuc_1100, the key bioactive outer membrane protein that activates TLR2 immune receptors. One proof-of-concept RCT showed improved insulin sensitivity (+28.6%), reduced insulinemia (−34.1%), and reduced total cholesterol (−8.7%) in overweight/obese adults. Efficacy appears to depend on baseline gut Akkermansia levels — individuals already replete may not benefit. EFSA approved the pasteurized form as a safe novel food. Caution in IBD patients — excessive mucin degradation could thin the mucosal barrier.
What Akkermansia supports
- Supports gut barrier integrity via mucus layer modulation
- May improve insulin sensitivity and reduce insulinemia in overweight individuals
- One RCT showed reduced total cholesterol
How much Akkermansia to take
Clinical studies typically use 25–100 mg of Akkermansia. Labels typically list mg of pasteurized powder. The landmark RCT (Depay 2019, n=40) used 10 billion cells/day (~50 mg pasteurized powder) for 3 months. Commercial products range 25–100 mg. Dose equivalence between mg and cell counts varies by manufacturer concentration.
- Effective range
- 25–100 mg
Clinical evidence
Limited clinical evidence. One proof-of-concept trial (40 participants) showed metabolic improvements; very early-stage evidence
Examine.com